# EDGAR Filing Document

**Accession Number:** 0001779170
**File Stem:** 0001225208-25-006214
**Filing Date:** 2025-6
**Character Count:** 13533
**Document Hash:** d8e2637fd5011ef60dea9e0dabc1f23f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001225208-25-006214.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0001225208-25-006214

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250630

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Monson Jonathan
- **CENTRAL INDEX KEY:** 0001779170

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11083
- **FILM NUMBER:** 251092827

**MAIL ADDRESS:**
- **STREET 1:** C/O BOSTON SCIENTIFIC CORPORATION
- **STREET 2:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BOSTON SCIENTIFIC CORP
- **CENTRAL INDEX KEY:** 0000885725
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 042695240
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234
- **BUSINESS PHONE:** 508-683-4000

**MAIL ADDRESS:**
- **STREET 1:** 300 BOSTON SCIENTIFIC WAY
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752-1234

## Ex-24

```

POWER OF ATTORNEY

	Know all by these present that the undersigned hereby constitutes and
appoints each of Vance R. Brown, Susan Thompson, Jonathan Robertson and Mary
Wiseman signing singly, the undersigned's true and lawful attorney-in-fact to:

(1)	execute for and on behalf of the undersigned, in the undersigned's
capacity as an executive officer and/or director of Boston Scientific
Corporation (the "Company"), Form ID, Forms 3, 4 and 5, and amendments thereto,
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

(2)	do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form ID,
Form 3,4 or 5 and file such form with the United States Securities and
Exchange Commission and any stock exchange or similar authority;

(3)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an executive officer and/or director of the Company, Forms 144 in accordance
with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules
and regulations thereunder; and

(4)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted.

	The undersigned acknowledges that the foregoing attorneys-in-fact,
in  serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's responsibilities
to comply with Section 16 of the Securities Exchange Act of 1934 or Rule 144
of the Securities Act of 1933, as amended.

	This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4 and 5 and Forms
144 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned
in a signed writing delivered to the foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 26 of June, 2025.

/s/ Jonathan R. Monson
_________________
Jonathan R. Monson

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Monson Jonathan<br><sub>(Last) (First) (Middle)</sub><br>300 BOSTON SCIENTIFIC WAY<br><sub>(Street)</sub><br>MARLBOROUGH, MA 01752-1234<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BOSTON SCIENTIFIC CORP [ BSX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-30 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP and CFO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 34727.0000 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | 2028-02-12<sup>(1)</sup> | Common Stock | 3462.0000<sup>(2)</sup> | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2029-02-13<sup>(4)</sup> | Common Stock | 7066.0000 | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(5)</sup> | 2027-02-14<sup>(5)</sup> | Common Stock | 2116.0000<sup>(6)</sup> | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(7)</sup> | 2026-02-16<sup>(7)</sup> | Common Stock | 990.0000<sup>(8)</sup> | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(9)</sup> | 2025-08-02<sup>(9)</sup> | Common Stock | 1090.0000<sup>(10)</sup> | <sup>(3)</sup> | D |  |
| Restricted Stock Units | <sup>(11)</sup> | 2026-12-01<sup>(11)</sup> | Common Stock | 3562.0000 | <sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(12)</sup> | 2028-02-15 | Common Stock | 12004.0000 | $27.0900 | D |  |
| Stock Option (Right to Buy) | <sup>(13)</sup> | 2031-02-17 | Common Stock | 14299.0000 | $37.5000 | D |  |
| Stock Option (Right to Buy) | <sup>(14)</sup> | 2029-02-21 | Common Stock | 8605.0000 | $40.1200 | D |  |
| Stock Option (Right to Buy) | <sup>(15)</sup> | 2030-02-18 | Common Stock | 10346.0000 | $42.1600 | D |  |
| Stock Option (Right to Buy) | <sup>(16)</sup> | 2029-07-01 | Common Stock | 10692.0000 | $42.9000 | D |  |
| Stock Option (Right to Buy) | <sup>(17)</sup> | 2032-02-16 | Common Stock | 13180.0000 | $44.1900 | D |  |
| Stock Option (Right to Buy) | <sup>(18)</sup> | 2031-08-02 | Common Stock | 15503.0000 | $45.8800 | D |  |
| Stock Option (Right to Buy) | <sup>(19)</sup> | 2033-02-14 | Common Stock | 12702.0000 | $47.2800 | D |  |
| Stock Option (Right to Buy) | <sup>(20)</sup> | 2033-12-01 | Common Stock | 10543.0000 | $56.1400 | D |  |
| Stock Option (Right to Buy) | <sup>(21)</sup> | 2034-02-12 | Common Stock | 14180.0000 | $64.9900 | D |  |
| Stock Option (Right to Buy) | <sup>(22)</sup> | 2035-02-13 | Common Stock | 7165.0000 | $106.1400 | D |  |

---

### Footnotes:

(1) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

(2) This amount represents the unvested portion of RSUs awarded on February 12, 2024, which will continue to vest in three remaining installments on the anniversary of the date of grant.

(3) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

(4) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

(5) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

(6) This amount represents the unvested portion of RSUs awarded on February 14, 2023, which will continue to vest in two remaining installments on the anniversary of the date of grant.

(7) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

(8) This amount represents the unvested portion of RSUs awarded on February 16, 2022, which will continue to vest in one remaining installment on the anniversary of the date of grant.

(9) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

(10) This amount represents the unvested portion of RSUs awarded on August 2, 2021, which will continue to vest in one remaining installment on the anniversary of the date of grant.

(11) Shares of common stock will be issued to the reporting person in full on December 1, 2026, the third anniversary of the date of grant.

(12) Grant to the reporting person of an option to purchase 12,004 shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.

(13) Grant to the reporting person of an option to purchase 14,299 shares of common stock vesting in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

(14) Grant to the reporting person of an option to purchase 8,605 shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.

(15) Grant to the reporting person of an option to purchase 10,346 shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

(16) Grant to the reporting person of an option to purchase 10,692 shares of common stock vesting in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant.

(17) Grant to the reporting person of an option to purchase 13,180 shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

(18) Grant to the reporting person of an option to purchase 15,503 shares of common stock vesting in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

(19) Grant to the reporting person of an option to purchase 12,702 shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

(20) Grant to the reporting person of an option to purchase 10,543 shares of common stock vesting in full on December 1, 2026, the third anniversary of the date of grant.

(21) Grant to the reporting person of an option to purchase 14,180 shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

(22) Grant to the reporting person of an option to purchase 7,165 shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

**Remarks:**
monsonpoa.txt

**Signature:** /s/ Susan Thompson, Attorney-in-Fact  
**Date:** 2025-06-30

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**